Sign In
Buy AVXL
$2.65
-0.140 (-5.03%)
At Close: Jun 03, 2026
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
08:00am, Friday, 22'nd May 2026
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative tr
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative tr
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
07:30am, Tuesday, 14'th Apr 2026
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
07:30am, Tuesday, 07'th Apr 2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
Anavex Life Sciences Provides Comprehensive Regulatory Update
07:30am, Monday, 30'th Mar 2026
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
10:02pm, Thursday, 26'th Mar 2026
NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL). Such investors are advis
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
10:40am, Wednesday, 25'th Mar 2026
This decision follows feedback from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which indicated it would not issue a positive opinion at this time.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
07:30am, Wednesday, 25'th Mar 2026
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group af
Findings underpin potential of Anavex' lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration Findings underpin potential of Anavex' lead candi
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Park
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
07:30am, Tuesday, 03'rd Mar 2026
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
07:30am, Wednesday, 25'th Feb 2026
NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
07:30am, Monday, 23'rd Feb 2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative t
Anavex Life Sciences (AVXL) Upgraded to Buy: Here's What You Should Know
01:02pm, Thursday, 12'th Feb 2026
Anavex Life Sciences (AVXL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
